A proliferation of new biotech products is on its way in the next decade — and it may overwhelm the regulatory system, according to a new report from the National Academies of Sciences, Engineering, and Medicine. This comes at a time when far-reaching deregulation looms, along with a government hiring freeze.
The Trump administration, of course, has suggested that the Food and Drug Administration, among other government agencies, must cut two regulations for every one that they adopt. Dr. Scott Gottlieb, his nominee to head the FDA, may have his own ideas on the subject.
That said, the report suggests that the current level of expertise available at the FDA, along with the Environmental Protection Agency and the Department of Agriculture, likely isn’t sufficient to address the burgeoning biotech sector. The report itself was actually commissioned by these three agencies, lending some insight into their general stance on the issue.
About the Author Reprints
